UNHNYSEHospital & Medical Service PlansFiscal year ends December 31
UNITEDHEALTH GROUP INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$406.88+5.45 (+1.36%)
Close on Oct 19, 2026
- Market cap
- $368.63B
- P/E (TTM)
- 26.2
- Dividend yield
- 2.15%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
88.7%+0.6 pts over 5 years
Operating margin
4.2%−4.5 pts over 5 years
Net margin
2.7%−3.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.8% | +11.4% | +11.7% | +11.0% | |
| Gross profit | +12.3% | +11.0% | +11.9% | +10.9% | |
| Operating income | -41.3% | -12.6% | -3.3% | +5.6% | |
| Net income | -16.3% | -15.7% | -4.8% | +7.6% | |
| EPS, diluted | -14.7% | -14.5% | -3.8% | +8.2% | |
| Free cash flow | -22.4% | -11.8% | -4.4% | +7.0% | |
| Dividend per share | +6.7% | +10.9% | +12.6% | +16.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | 6.0% | 8.3% | 4.0% | |
| Current ratio | 0.69 | 0.74 | 0.79 | |
| Net debt to EBITDA | 1.50× | 1.05× | 2.32× | |
| Interest coverage | 12.1× | 13.5× | 4.7× | |
| Inventory turnover | – | – | 14.3× | |
| Capex to revenue | 0.9% | 0.8% | 0.8% | |
| Diluted shares | 968M | 961M | 911M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Unitedhealth generated $121.52B from operations and spent $83.79B on capital expenditure, dividends and share buybacks. 19% of that went back into the business.
Generated
$121.52B
Used
$83.79B
Capital expenditure$15.76B19%Dividends$33.48B40%Share buybacks$34.55B41%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$12.06B
- Cash generatingOperating cash flow above zero$19.70B
- Return on assets improvedROA up on the prior year5.3% → 4.0%
- Earnings backed by cashOperating cash flow above net income$19.70B vs $12.06B
- Less leverageLong-term debt to assets fell24.3% → 23.4%
- Better liquidityCurrent ratio rose0.83 → 0.79
- No dilutionShare count did not rise929M → 911M
- Gross margin improvedGross margin up on the prior year88.33% → 88.68%
- More efficientAsset turnover rose1.46 → 1.50